Cargando…

Association of intranasal esketamine, a novel ‘standard of care’ treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice

INTRODUCTION: Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits. The objective of this observational study is to elucidate the associatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vazquez, Gustavo, Gutierrez, Gilmar, Rosenblat, Joshua, Schaffer, Ayal, Swainson, Jennifer, Karthikeyan, Ganapathy, Ravindran, Nisha, Lam, Raymond W, Do, André, Giacobbe, Peter, Hawken, Emily, Milev, Roumen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Mental Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438206/ https://www.ncbi.nlm.nih.gov/pubmed/36581972 http://dx.doi.org/10.1136/bmjopen-2022-060967

Ejemplares similares

Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study
por: Gutierrez, Gilmar, et al.
Publicado: (2022)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis
por: Zhan, Zhiqing, et al.
Publicado: (2021)

Effectiveness of integrated treatment for eating disorders in Spain: protocol for a multicentre, naturalistic, observational study
por: Grau Touriño, Antoni, et al.
Publicado: (2021)

Intranasal Esketamine administration in catatonia: a case report.
por: Romay, J., et al.
Publicado: (2023)

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
por: Dadiomov, David
Publicado: (2020)

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
por: Sapkota, Alisha, et al.
Publicado: (2021)

Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
por: Skala, Katrin, et al.
Publicado: (2023)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
por: Capuzzi, Enrico, et al.
Publicado: (2021)

Intranasal esketamine use in bipolar disorder: A case report
por: Skriptshak, Courtney, et al.
Publicado: (2021)

The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022)

Transcranial Magnetic Stimulation of the Supplementary Motor Area in the Treatment of Obsessive-Compulsive Disorder: A Multi-Site Study
por: Hawken, Emily R., et al.
Publicado: (2016)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
por: Olivola, Miriam, et al.
Publicado: (2022)

Response of Depression to Botulinum Toxin Treatment: Agitation as a Predictor
por: Milev, Roumen
Publicado: (2015)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
por: Carter, Maximilian, et al.
Publicado: (2022)

Median effective dose of esketamine for intranasal premedication in children with congenital heart disease
por: Huang, Jiajia, et al.
Publicado: (2023)

Mortality in dementia with Lewy bodies compared with Alzheimer’s dementia: a retrospective naturalistic cohort study
por: Price, Annabel, et al.
Publicado: (2017)

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
por: Wang, Sheng-Min, et al.
Publicado: (2021)

A Comparison of Intranasal Dexmedetomidine, Esketamine or a Dexmedetomidine-Esketamine Combination for Induction of Anaesthesia in Children: A Randomized Controlled Double-Blind Trial
por: Lu, Xinlei, et al.
Publicado: (2022)

Evaluating the Efficacy of Web-Based Cognitive Behavioral Therapy for the Treatment of Patients With Bipolar II Disorder and Residual Depressive Symptoms: Protocol for a Randomized Controlled Trial
por: Gutierrez, Gilmar, et al.
Publicado: (2023)

Tulsa 1000: a naturalistic study protocol for multilevel assessment and outcome prediction in a large psychiatric sample
por: Victor, Teresa A, et al.
Publicado: (2018)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

Did the suicide barrier work after all? Revisiting the Bloor Viaduct natural experiment and its impact on suicide rates in Toronto
por: Sinyor, Mark, et al.
Publicado: (2017)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
por: Keeler, Johanna Louise, et al.
Publicado: (2023)

Common factors, Responsiveness and Outcome in Psychotherapy (CROP): study protocol for a naturalistic prospective cohort study of psychotherapy in Denmark
por: Lauritzen, Line Rettig, et al.
Publicado: (2023)

Mental health and functional impairment outcomes following a 6-week intensive treatment programme for UK military veterans with post-traumatic stress disorder (PTSD): a naturalistic study to explore dropout and health outcomes at follow-up
por: Murphy, Dominic, et al.
Publicado: (2015)

Fetal alcohol spectrum disorders from childhood to adulthood: a Swedish population-based naturalistic cohort study of adoptees from Eastern Europe
por: Landgren, Valdemar, et al.
Publicado: (2019)

Effects, experiences, and impact of stigma on patients with bipolar disorder
por: Mileva, Viktoria R, et al.
Publicado: (2013)

The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
por: Dijkstra, Francis M, et al.
Publicado: (2022)

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
por: Martiadis, V., et al.
Publicado: (2022)

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk
por: Martiadis, V., et al.
Publicado: (2023)

Fostering practice-based evidence through routine outcome monitoring in a university psychotherapy service for common mental health problems: a protocol for a naturalistic, observational study
por: Valdiviezo-Oña, Jorge, et al.
Publicado: (2023)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

Combining Ketamine and Internet-Based Cognitive Behavioral Therapy for the Treatment of Posttraumatic Stress Disorder: Protocol for a Randomized Controlled Trial
por: Philipp-Muller, Aaron Emile, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kj6u9icksbvk20p6qsbdel7cps